Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
2019
Background
Response rates are primary endpoints in many oncology trials; however, correlation with overall survival (OS) is not uniform across cancer types, treatments, or lines of therapy. This study explored the association between objective response (OR) and OS in patients with chemotherapy-refractory metastatic Merkel cell carcinoma who received avelumab (anti-PD-L1).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
36
References
16
Citations
NaN
KQI